Palliation of Dyspnea With Morphine in Patients With Interstitial Lung Disease

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02622022

Acronym

MORPHILD

Enrollment

Registered

2015-12-04

Start date

2016-01-31

Completion date

2019-02-06

Last updated

2019-04-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Interstitial Lung Disease, Dyspnea, Morphine

Keywords

randomised, placebo controlled, clinical trial

Brief summary

36 patients with interstitial lung disease will be randomized to 1 weeks treatment with morphine hydrochloride as oral linctus 5 mg, four times a day, and 5 mg as needed up to 4 times a day, or corresponding doses of placebo. VAS score for dyspnea will be evaluated after 1 hour and 1 week at follow up. Other questionnaires will also be evaluated (GAD-7, K-BUILD, Leicester score)

Interventions

DRUGMorphine hydrochloride

OTHERPlacebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 110 Years

Healthy volunteers

Inclusion criteria

* A diagnosis of interstitial lung disease (IPF, NSIP, RA-ILS, Scl-ILS, MCTD-ILS, asbestous, drug induced ILD, unclassified ILD) * Dyspnea corresponding to Medial Research Councils (MRC) dyspnea score ≥ 3 * Written consent * Age ≥ 18 years * Competent * For fertile women: Negative pregnancy test * For fertile and sexually active participants: Use of safe anti-conceptionals

Exclusion criteria

* Ongoing infection * Decreased lung function to a degree which makes any form of respiratory depression life threatening * Treatment with morphine or morphine analogues * Allergy towards morphine hydrochloride

Design outcomes

Primary

Measure	Time frame
VAS dyspnea score	1 week

Secondary

Measure	Time frame	Description
Oxygen saturation	1 hour and 1 week	Peripheral oxygen saturation will be measured after first dose of morphine and placebo as well as after 1 week follow up
K-bild questionnaire	1 week	questionnaire regarding interstitial lung specific life quality
GAD-7 questionnaire	1 week	VAlidatet score for anxiety and depression
6 min walk test	1 hour and 1 week	—
Leicester Score	1 week	cough related score

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 26, 2026